FRET Assay for MSI2-RNA Interaction Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers involving the MSI2 pathway, such as pancreatic, lung, and colon cancer, are resistant, necessitating the development of novel therapeutic strategies that target protein-RNA interactions, particularly the MSI2-RNA binding functions.
Innovation Solution
A method using Fluorescence Resonance Energy Transfer (FRET)-based assays to identify small molecule modulators, specifically inhibitors or enhancers, of protein-RNA interactions, including MSI2-RNA interactions, by detecting changes in FRET signals upon introducing agents, which can be applied in high-throughput screening to identify potential therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for MSI2 pathway cancers, then treatment simplicity is maintained, but treatment effectiveness deteriorates due to drug resistance
Solution Approach 1:
The patent introduces FRET-based molecular probes as intermediaries to detect and characterize protein-RNA interactions. These probes consist of donor and acceptor fluorophores that emit signals when in proximity, enabling indirect detection of MSI2-RNA binding events without directly interfering with the biological interaction, thus maintaining treatment effectiveness while enabling precise molecular characterization
Solution Approach 2:
The patent replaces traditional mechanical or chemical screening methods with optical detection systems. By substituting physical separation or chemical reaction-based detection with fluorescence resonance energy transfer measurements, the system achieves higher sensitivity and specificity in identifying effective therapeutic compounds against MSI2 pathway cancers
2Measurement precision
If FRET-based assays are used to identify modulators, then identification precision improves, but assay complexity increases
Solution Approach 1:
The patent segments the detection system into distinct functional modules: donor fluorophore labeling of one molecule, acceptor fluorophore labeling of another molecule, and separate detection channels. This segmentation allows each component to be optimized independently while maintaining overall assay precision, and facilitates high-throughput screening by enabling parallel processing of multiple samples
Solution Approach 2:
The patent utilizes changes in fluorescence emission parameters (intensity, wavelength, lifetime) as indicators of molecular interaction. By monitoring these optical parameters rather than physical or chemical properties, the assay achieves high measurement precision. The method further employs ratiometric measurements and time-resolved detection to eliminate background interference, enhancing precision while managing complexity through standardized protocols
3Productivity
If high-throughput screening is implemented, then compound identification speed improves, but resource consumption increases
Solution Approach 1:
The patent combines multiple detection functions into a single FRET assay platform. By merging binding detection, specificity assessment, and affinity measurement into one integrated fluorescent assay, the system achieves high throughput without proportionally increasing reagent consumption. The dual-fluorophore system allows simultaneous monitoring of interaction presence and strength, eliminating the need for separate assay steps
Solution Approach 2:
The patent employs sensitive fluorescence detection that requires minimal sample volumes and low reagent concentrations. By utilizing the high sensitivity of optical detection, the assay can identify active compounds with smaller amounts of labeled proteins and RNAs compared to traditional methods. Time-resolved fluorescence measurements further enhance signal-to-noise ratios, allowing reduced reagent doses while maintaining detection capability across high-throughput formats
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively identifies inhibitors of MSI2-RNA interactions, leading to the development of novel cancer therapeutic agents that can target MSI2-expressing cancers, enhancing treatment options for pancreatic, lung, and colon cancers.
Implementation Method 1
A method using Fluorescence Resonance Energy Transfer (FRET)-based assays to identify small molecule modulators, specifically inhibitors or enhancers, of protein-RNA interactions, including MSI2-RNA interactions, by detecting changes in FRET signals upon introducing agents
Data Source
AI summary
Disclosed are methods for identifying small molecule modulators of protein-RNA interactions that could potentially function as therapeutic agents in cancer treatment. Methods of identifying inhibitors of the RNA-binding functions of MSI2, as well as inhibitors identified thereof, are also disclosed.